New drug cocktail shows promise for tough ovarian cancers

NCT ID NCT03462342

Completed Disease control Sponsor: University of Pennsylvania Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a combination of two drugs, AZD6738 and olaparib, in 123 women with recurrent ovarian cancer. The goal was to see if the combo is safe and how well it shrinks tumors or delays cancer growth. Participants had either platinum-sensitive or platinum-resistant cancer, and some had already stopped responding to PARP inhibitors. The trial looked at side effects, tumor response, and how long patients lived without their cancer getting worse.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: AZD6738 (ATR inhibitor) and olaparib (PARP inhibitor)
What this could lead to: If successful, this combination could offer a new treatment option for women with recurrent ovarian cancer, potentially slowing disease progression even after other treatments have failed.
What could go wrong: This is a Phase 2 trial with 123 participants, so results are still early. The combination may cause significant side effects, and not all patients may respond, especially those resistant to PARP inhibitors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FALLOPIAN TUBE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

fallopian tube cancer ovarian carcinoma ovarian serous adenocarcinoma primary peritoneal carcinoma serous adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIGH GRADE SEROUS CARCINOMA

Contacts and locations

Locations

Dana-Farber Cancer Institute

Boston, Massachusetts, 02215, United States
Hospital of the University of Pennsylvania

Philadelphia, Pennsylvania, 19104, United States
Johns Hopkins University School of Medicine

Baltimore, Maryland, 21287, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.